Effects of inulin-type fructans on lipid metabolism in man and in animal models

Michel Beylot*

Inserm U 499, Faculté RTH Laennec, Rue G Paradin, Lyon 69008, France

Studies in rodents show that inulin and oligofructose can reduce the plasma levels of cholesterol and triacylglycerols (TG). In addition, they can oppose TG accumulation in liver and have favourable effects on hepatic steatosis. The hypotriglyceridaemic effect is due to a reduction in hepatic re-esterification of fatty acids, but mainly in the expression and activity of liver lipogenesis, resulting in lower hepatic secretion rate of TG. This repression of lipogenesis is not observed in adipose tissue. The effect on liver lipogenesis can be explained by reduced insulin/glucose levels or by a selective exposure of the liver to increased amounts of propionic acid produced in the large intestine during fermentation of non-digestible carbohydrates. The decrease in plasma cholesterol could also be due to inhibition of cholesterol synthesis by propionic acid or to modifications in the bile acid metabolism. Studies in man yield more conflicting results with a decrease or no effects on plasma lipid levels, and, when a decrease is observed, more marked effects on TG than on cholesterol and more consistent action of inulin than of oligofructose. Besides the difference in the dose of inulin or oligofructose used, differences in metabolic status could play a role in this discrepancy between man and animals since reduction in plasma TG is observed in man mainly in a situation of increased liver lipogenesis (high-carbohydrate diet, obesity, hypertriglyceridaemia). The effects on plasma cholesterol appear also more marked in hyperlipidaemic subjects than in healthy controls, suggesting that inulin and oligofructose have beneficial effects in these types of subjects.

Lipid: Cholesterol: Triacylglycerols: Fibre: Inulin: Oligofructose

Atherosclerosis is a leading cause of death in industrialised societies. Therefore, a reduction in risk factors for atherosclerosis, such as elevated concentrations of plasma total cholesterol and plasma LDL-cholesterol (Klag et al. 1993) and raised concentrations of plasma triacylglycerols (TG: Hokanson & Austin, 1996), is a major goal in public health. Such reductions can be achieved with the use of compounds inhibiting cholesterol synthesis (West of Scotland Coronary Prevention Study Group, 1996), is a major goal in public health. Such reductions can be achieved with the use of compounds inhibiting cholesterol synthesis (West of Scotland Coronary Prevention Study Group, 1998) or activating nuclear receptors, such as PPARα (Forcheron et al. 2002). These reductions can also be obtained at least in part through dietary advice (Jones, 1997), a less expensive approach that can be used for large cohorts of subjects. Increasing the amount of prebiotics in the diet, such as the inulin-type fructans, is one of these possible dietary approaches since it may help to reduce plasma lipid concentrations (Roberfroid, 1993; Delzenne & Kok, 2001). Studies in animals have consistently shown such lipid-lowering actions. Studies in man have produced more conflicting findings, but several do support the usefulness of inulin and/ or oligofructose in reducing plasma lipid levels. This review presents results on lipid metabolism in animal and human subjects and discusses possible mechanisms involved in the action of inulin-type fructans.

Studies in animals

Most of the studies have been performed on rats and have investigated the effects of oligofructose, but some have also been conducted on hamsters (Trautwein et al. 1998) or dogs (Flickinger et al. 2003) and focused on the effects of inulin (Trautwein et al. 1998).

Effects on metabolism of triacylglycerols

Studies conducted on lean rats fed a high-carbohydrate diet supplemented (10 % w/w) with oligofructose have consistently shown a decrease in plasma TG levels (Delzenne et al. 1993; Fiodaliso et al. 1995; Kok et al. 1996b), both in the fasted and in the fed states. This decrease is associated with lower concentrations of plasma phospholipids (Delzenne et al. 1993) and is mostly due to a decrease in the concentration of plasma VLDL-TG in the post-absorptive state (Fiodaliso et al. 1995). This TG-lowering effect of oligofructose has also been observed in rats fed a sucrose or a fructose-enriched diet (Aghelli et al. 1998; Busserolles et al. 2003) and in rats fed a fibre-free diet (Delzenne & Kok, 1999). Furthermore, oligofructose has been reported to decrease postprandial TG concentrations in rats fed a high-fat diet (Kok et al. 1998b) and inulin to lower plasma TG in hamsters (Trautwein et al. 1998) and dogs (Flickinger et al. 2003). Some studies have shown a decrease in the intra-hepatic concentration of TG with oligofructose (Daubioul et al. 2002; Busserolles et al. 2003), suggesting that the hypotriglyceridaemic action results rather from a decrease in the hepatic synthesis of TG than from a higher clearance of TG-rich lipoprotein.

The concentration of plasma NEFA, an important source of fatty acids for liver TG synthesis, was not lowered by oligofructose, suggesting that hepatic uptake of NEFA is not modified (Daubioul et al. 2002). There is no evidence for an increased hepatic oxidation
of fatty acids since the activity of carnitine–palmitoyl transferase 1, the enzyme controlling the entry of long-chain fatty acyl-CoA in mitochondria for oxidation, is unchanged (Delzenne & Kok, 1999). However, hepatocytes isolated from oligofructose-fed rats have a decreased capacity to esterify palmitate (Kok et al. 1996b). The main hepatic action of oligofructose appears to be a decreased lipogenic capacity (Kok et al. 1996b). Actually, oligofructose induces a simultaneous decrease in the hepatic expression and activity of the lipogenic enzymes of acetyl-CoA carboxylase, malic enzyme, ATP citrate lyase and fatty acid synthase (Aghelli et al. 1998; Delzenne & Kok, 1999). This effect was specific for the liver since oligofructose induced, on the contrary, a moderate increase in fatty acid synthase activity in white adipose tissue (Aghelli et al. 1998). This effect of oligofructose may depend on the metabolic status of the rats as this oligosaccharide was shown to reduce hepatic steatosis without any decrease in the raised plasma TG concentrations in obese, insulin-resistant Zucker rats (Daubioul et al. 2000). Such a discrepancy between the effects of oligofructose on hepatic and plasma TG levels was also observed in fructose-fed rats (Kok et al. 1998a). Moreover, oligofructose induced only a moderate decrease in malic enzyme activity in Zucker rats, without any changes in the activity of other lipogenic enzymes (Daubioul et al. 2000). In this model, the decrease in liver TG content could be due to an increased secretion of VLDL-TG, but the mechanism remains unclear. Lastly, the addition of oligofructose to a high-fat diet in rats reduced the postprandial TG levels by 50% (Kok et al. 1998b), suggesting that oligofructose could also decrease plasma TG by enhancing TG catabolism.

The principal mechanisms of the hypotriglyceridaemic action of inulin-type fructans in animals thus appear to be a decreased expression and activity of the liver lipogenic pathway. However, the link between fructans ingestion and decreased hepatic lipogenesis is still unclear. Mainly nutrients and hormones control hepatic expression of lipogenic genes, insulin and glucose stimulate the expression of lipogenic genes while glucagon and PUFAs inhibit it (Girard et al. 1994). These effects are mediated through modifications of the expression and/or the activity of the transcription factors sterol responsive element binding protein 1c (Foufelle & Ferré, 2002), carbohydrate responsive element binding protein (Uyeda et al. 2002) and liver X receptor (Joseph et al. 2002) – all stimulating the expression of lipogenic genes. At present, there are no data on the possible effect of fructans on these transcription factors. Since glucose and insulin have a major stimulatory role in the control of lipogenesis, a decrease in basal or postprandial glucose and insulin levels by inulin-type fructans could be involved. Surprisingly, these parameters were measured only in some studies. The available data are somewhat contradictory and the effects of inulin-type fructans could be dependent on the physiological (basal or postprandial) or disease (insulin-resistance, diabetes) conditions. Rats given oligofructose (10% in the diet) for 30 d had a moderate decrease in postprandial glucose and insulin concentrations (Kok et al. 1996b; Delzenne & Kok, 1999), but there were no modifications of the response to an oral glucose load, or only a decrease in the insulin-naïve response (Delzenne & Kok, 1999). Oligofructose induced a moderate decrease in basal glucose level of sucrose-fed rats without modification of the response to oral glucose load (Aghelli et al. 1998); insulin was not modified, as in fructose-fed rats (Busserolles et al. 2003). The basal values and the response of glucose and insulin to oral glucose load were not modified in obese Zucker rats (Daubioul et al. 2000). Oligofructose decreased glucose levels in diabetic (streptozotocin-induced) rats, but this appeared to be linked to some increase in residual insulin secretion. Overall, the modifications of glucose and insulin concentrations during administration of oligofructose in rats are limited and their role in the decreased lipogenic capacity of the liver remains to be established.

Inulin-type fructans may also decrease liver lipogenesis through increased production of SCFA in the large bowel or through the modification of the intestinal production of cytokines or incretins. Fermentation of non-digestible carbohydrates in the colon produces SCFA and oligofructose feeding leads to an increase of the portal concentrations of acetate and, more markedly, of propionate (Delzenne & Daubioul, 2000; Daubioul et al. 2002). Acetate is a lipogenic substrate, whereas propionate inhibits lipogenesis in isolated hepatocytes of normal (Wright et al. 1990; Demigné et al. 1995) and Zucker rats (Daubioul et al. 2002). This action of propionate could involve a competition between propionate and acetate for the transporter of acetate into hepatocytes (Delzenne & Williams, 2002). Oligofructose administration in the diet of rats increases the plasma and intestinal concentration of glucose-dependent insulinotropic polypeptide 1 (GLP-1) in the caecum (Kok et al. 1998a). These peptides are released by the enterocyte cells of the intestine and they enhance postprandial insulin secretion. Their possible role in the hypotriglyceridaemic effect of oligofructose remains to be clarified. GIP stimulates lipoprotein lipase activity in the adipose tissue (Knapper et al. 1995) and lowers the plasma TG response to an oral fat load in rats (Ebert et al. 1991). In addition, GIP decreases incorporation of labelled C from glucose into lipids in vitro and thus, probably, decreases hepatic lipogenesis (Kok et al. 1998a). However, GIP stimulates lipogenesis in adipose tissue (Oben et al. 1991) and reinforces the stimulatory effect of insulin on hepatic lipogenesis (Zanpelas et al. 1995). Therefore, its overall effect in vivo and its possible implication in the action of oligofructose on liver lipogenesis remain unclear. There are presently no data on the effect of GLP-1 on hepatic lipogenesis. Another possible mechanism of action of oligofructose, which remains to be investigated, could be the modification of intestinal bacterial content and intestinal permeability, a reduction of endotoxaemia and production of cytokines like IL-6 and TNF-α that can both stimulate hepatic lipogenesis (Brass & Vetter, 1994; Lawler et al. 1998; Wigg et al. 2001).

**Effects on cholesterol metabolism**

Studies on the effect of inulin and oligofructose on cholesterol in animals produced more conflicting results. The addition of oligofructose to the diet did not decrease plasma cholesterol in lean (Delzenne et al. 1993; Kok et al. 1996a; Aghelli et al. 1998) or obese Zucker (Daubioul et al. 2000) rats or in dogs (Flickinger et al. 2003). In another, more prolonged study, 10% dietary oligofructose induced a moderate (−15%) reduction of plasma cholesterol in rats (Fiordaliso et al. 1995). Lastly, oligofructose prevented the hypercholesterolaemic effect of a high-fat diet in rats. The effects of inulin appear more consistent. Although inulin had no significant effect in dogs (Flickinger et al. 2003), it had a significant hypocholesterolaemic effect in rats (Levrat et al. 1994) and a marked effect in hamsters (Trautwein et al. 1998; a more appropriate model because of better similarities with human cholesterol metabolism). The reduction in cholesterol level was limited to esterified cholesterol (Fiordaliso et al. 1995).
and to the VLDL fraction without changes in LDL- and HDL-cholesterol (Fiordaliso et al. 1995; Trautwein et al. 1998).

Several mechanisms have been proposed to explain the hypocholesterolaemic effect. The limitation of the decrease in plasma cholesterol to the VLDL fraction suggests that the decreased synthesis and secretion of VLDL has a major role. It has been proposed that propionate, whose intestinal production is increased by inulin-type fructans administration, could inhibit hepatic cholesterol synthesis (Demigné et al. 1995), but other studies did not show convincing evidence for this effect (Nishina & Freeland, 1990; Levrat et al. 1994). Intestinal absorption of cholesterol does not seem to be impaired (Trautwein et al. 1998). Although inulin-type fructans do not share all the properties of other viscous fibres such as psyllium (Schneeman, 1999; Fernandez, 2001), they may increase faecal bile acid excretion (Levrat et al. 1994; Trautwein et al. 1998). They could, therefore, stimulate liver synthesis of bile acids from cholesterol and this could contribute to their cholesterol-lowering action.

Studies in man

While data obtained for animals showed convincing lipid-lowering properties of inulin-type fructans, studies conducted in man are more conflicting. Tables 1 and 2 summarise the results obtained for control subjects (Table 1) and for type 2 diabetic or hyperlipidaemic patients (Table 2).

Of the five studies conducted on healthy subjects, the two investigating the effect of oligofructose found no modifications of plasma lipids, glucose or insulin concentrations (Luo et al. 1996; Van Dokum et al. 1999). Inulin, investigated in four studies, had no effect in two (Pedersen et al. 1997; Van Dokum et al. 1999) and induced a decrease in TG in one (Letexier et al. 2003a), while both TG and cholesterol were decreased in the last study (Brighenti et al. 1999). Luo et al. (1996) investigated the effect of oligofructose (20 g/d in cookies) on twelve men in a randomised crossover design with a 4-week treatment period. There was a small decrease in hepatic glucose production, but no changes in glucose, insulin, TG or cholesterol concentrations. Pedersen et al. (1997) observed no effect on plasma lipids in sixty-four young women ingesting inulin daily (14 g daily for 4 weeks in a randomised, double-blind, crossover design). Van Dokum et al. (1999) investigated the effects of inulin and oligofructose (15 g daily for 3 weeks in a randomised, double-blind, design on twelve healthy men and found no modifications of glucose, insulin or plasma lipid levels by either of the fructans used. In contrast, Brighenti et al. (1999) found a marked reduction in the plasma TG levels and a moderate decrease in plasma cholesterol in twelve men consuming 9 g inulin/d. Lastly, Letexier et al. (2003a) observed a 16% decrease in plasma TG in eight control subjects ingesting 10 g inulin/d (randomised, double-blind, crossover design); in this last study, all the subjects consumed a carefully controlled isoenergetic, but moderately high, carbohydrate (55% of energy intake) diet.

More promising results were obtained in type 2 diabetic patients and mostly in hyperlipidaemic subjects. Yamashita et al. (1984) investigated the effect of a 14 d administration of oligofructose (8 g/d) on eighteen patients with uncontrolled diabetes. They observed a small decrease in post-absorptive glucose (8%) and total cholesterol (6%) that was due to a reduction in LDL-cholesterol. HDL-cholesterol, TG and NEFA were not modified.

**Table 1. Summary of the effects of inulin and oligofructose on healthy human subjects**

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Fructans (g)</th>
<th>Design</th>
<th>Lipids</th>
<th>Glucose, IRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luo et al. (1996)</td>
<td>12 men OFS, 20</td>
<td>4 weeks, DB, CO</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Pedersen et al. (1997)</td>
<td>66 women Inulin, 14</td>
<td>4 weeks, DB, CO</td>
<td>NS</td>
<td>nd</td>
</tr>
<tr>
<td>Brighenti et al. (1999)</td>
<td>12 men Inulin, 9</td>
<td>4 weeks, parallel</td>
<td>TG – 27%</td>
<td>NS</td>
</tr>
<tr>
<td>Van Dokum et al. (1999)</td>
<td>12 men Inulin, 15</td>
<td>3 weeks, DB</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Letexier et al. (2003a)</td>
<td>4 men, 4 women Inulin-HP, 10</td>
<td>6 weeks, DB, CO</td>
<td>TG – 16%</td>
<td>NS</td>
</tr>
</tbody>
</table>

**Table 2. Summary of the effects of inulin and oligofructose on diabetic and hyperlipidaemic human subjects**

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Fructans (g)</th>
<th>Design</th>
<th>Lipids</th>
<th>Glucose, IRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yamashita et al. (1984)</td>
<td>18 NIDDM OFS, 8</td>
<td>2 weeks, DB, parallel</td>
<td>Chol – 6%</td>
<td>Glucose</td>
</tr>
<tr>
<td>Luo et al. (2000)</td>
<td>10 NIDDM OFS, 20</td>
<td>4 weeks, DB, CO</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Alles et al. (1999)</td>
<td>20 NIDDM OFS, 15</td>
<td>3 weeks, SB, CO</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Hidaka et al. (1991)</td>
<td>37 HC OFS, 20</td>
<td>5 weeks, DB, parallel</td>
<td>Chol – 8%</td>
<td>NS</td>
</tr>
<tr>
<td>Davidson et al. (1998)</td>
<td>21 HC Inulin, 18</td>
<td>6 weeks, DB, CO</td>
<td>Chol – 9%</td>
<td>nd</td>
</tr>
<tr>
<td>Jackson et al. (1999)</td>
<td>54 HC, HTG Inulin, 10</td>
<td>8 weeks, DB, parallel</td>
<td>TG – 19%</td>
<td>IRI</td>
</tr>
<tr>
<td>Causey et al. (2000)</td>
<td>12 HTG Inulin, 20</td>
<td>3 weeks, DB, CO</td>
<td>TG – 14%</td>
<td>NS</td>
</tr>
<tr>
<td>Balcazar et al. (2003)</td>
<td>12 HC, HTG Inulin, 7</td>
<td>4 weeks, DB, parallel</td>
<td>Chol – 20%</td>
<td>NS</td>
</tr>
</tbody>
</table>

**Table 3. Summary of the effects of inulin and oligofructose on diabetic and hyperlipidaemic human subjects**

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Fructans (g)</th>
<th>Design</th>
<th>Lipids</th>
<th>Glucose, IRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yamashita et al. (1984)</td>
<td>18 NIDDM OFS, 8</td>
<td>2 weeks, DB, parallel</td>
<td>Chol – 6%</td>
<td>Glucose</td>
</tr>
<tr>
<td>Luo et al. (2000)</td>
<td>10 NIDDM OFS, 20</td>
<td>4 weeks, DB, CO</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Alles et al. (1999)</td>
<td>20 NIDDM OFS, 15</td>
<td>3 weeks, SB, CO</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Hidaka et al. (1991)</td>
<td>37 HC OFS, 20</td>
<td>5 weeks, DB, parallel</td>
<td>Chol – 8%</td>
<td>NS</td>
</tr>
<tr>
<td>Davidson et al. (1998)</td>
<td>21 HC Inulin, 18</td>
<td>6 weeks, DB, CO</td>
<td>Chol – 9%</td>
<td>nd</td>
</tr>
<tr>
<td>Jackson et al. (1999)</td>
<td>54 HC, HTG Inulin, 10</td>
<td>8 weeks, DB, parallel</td>
<td>TG – 19%</td>
<td>IRI</td>
</tr>
<tr>
<td>Causey et al. (2000)</td>
<td>12 HTG Inulin, 20</td>
<td>3 weeks, DB, CO</td>
<td>TG – 14%</td>
<td>NS</td>
</tr>
<tr>
<td>Balcazar et al. (2003)</td>
<td>12 HC, HTG Inulin, 7</td>
<td>4 weeks, DB, parallel</td>
<td>Chol – 20%</td>
<td>NS</td>
</tr>
</tbody>
</table>
No precise data on diet were given, making it difficult to conclude whether these effects are due to changes in diet or due to the addition of oligofructose. In contrast, two more recent studies (Alles et al. 1999; Luo et al. 2000) found no significant effect on either glucose or lipid (TG, total, LDL- and HDL-cholesterol, NEFA) concentrations, despite higher doses of oligofructose (15 and 20 g, crossover, placebo-controlled studies). The most encouraging results were observed in hyperlipidaemic subjects. The only study investigating the effect of oligofructose in such subjects found a moderate decrease of total plasma cholesterol (Hidaka et al. 1991). Four studies investigated the effect of inulin in subjects with moderate hypercholesterolaemia (Davidson et al. 1998; Davidson & Maki, 1999) or with raised TG and cholesterol concentrations (Jackson et al. 1999; Causey et al. 2000; Balcazar-Munoz et al. 2003). Balcazar-Munoz et al. (2003) compared the effect of inulin (7 g/d) and placebo (randomised, double-blind study) on twelve obese, hyperlipidaemic subjects. Inulin decreased both TG (27 %) and total cholesterol (20 %), with a decrease in both VLDL- and LDL-cholesterol. Insulin sensitivity was not modified. The other studies found, despite the use of higher inulin doses (10–20 g/d), significant decreases only in cholesterol (Davidson et al. 1998; Davidson & Maki, 1999) or TG (Jackson et al. 1999; Causey et al. 2000). In the study of Jackson et al. (1999), the decrease in TG was all the more important since the initial value was high; in addition, basal insulin levels were also decreased and this fall in insulinemia may have played a role in the decrease in TG concentration.

Comparisons between animal and human studies

Studies in animals show consistent effects of inulin-type fructans on plasma TG levels and, to a lesser degree, on cholesterol concentrations, whereas more conflicting results are observed in man. Several explanations for this discrepancy between human and animal studies can be proposed. The first, and simplest one, is the use of much higher doses of oligofructose or inulin in animal studies. The use of comparable doses in man is precluded by the risk of uncomfortable gastrointestinal side-effects. However, in human studies, significant results were observed with low doses (7–10 g in Brighenti et al. 1999; Balcazar-Munoz et al. 2003; Letexier et al. 2003a), while higher doses (15–20 g) induced no or less important effects (Luo et al. 1996; Pedersen et al. 1997; Van Dokum et al. 1999). Another explanation relates to the main mechanism proposed for the hypotriglyceridaemic effect of inulin-type fructans in animals: inhibition of hepatic de novo lipogenesis. In man, hepatic de novo lipogenic rate is low and contributes only a few percent to the TG secreted by the liver (Diraison & Beylot, 1998). Therefore, only modest effects of the inhibition of hepatic lipogenesis can be expected unless its activity is previously raised by nutritional or pathological factors. Indeed, a significant hypotriglyceridaemic effect of inulin was observed in subjects receiving a controlled, moderately high, carbohydrate diet, a situation known to stimulate hepatic lipogenesis (Hudgins et al. 1996; Letexier et al. 2003b), and the decrease in TG was related, as during animal studies, to a reduction in hepatic lipogenesis (Letexier et al. 2003a). This could also explain the more consistent effect of inulin in human subjects with obesity and hypertriglyceridaemia than in control, healthy subjects, since obese and hypertriglyceridaemic subjects have also an enhanced hepatic lipogenic rate (Diraison et al. 2002; Forcheron et al. 2002). Lastly, difficulties in controlling nutrient intake, and, therefore, variations in this intake during the course of the studies, could also contribute to the relative discrepancy between human and animal studies. The precise mechanism of the cholesterol-lowering effect of inulin-type fructans in man remains elusive, as it does for studies in animals. The finding of a simultaneous decrease in VLDL-cholesterol and TG (Balcazar-Munoz et al. 2003) suggests that a decrease in the secretion of VLDL and, therefore, of cholesterol by the liver could contribute. A decrease in hepatic cholesterol synthesis may participate in this reduction of cholesterol secretion by the liver since propionate has been shown to induce a moderate reduction in the incorporation of labelled acetate into cholesterol (Wolever et al. 1995). A decrease in intestinal cholesterol absorption or an increase in bile acids synthesis from cholesterol secondary to a reduced reabsorption of bile acids seems unlikely since neither faecal bile acids excretion (Ellegård et al. 1997; Brighenti et al. 1999) nor cholesterol excretion (Ellegård et al. 1997) was modified in man by inulin.

Conclusions

It is clear that dietary inulin-type fructans have TG- and cholesterol-lowering effects in rodents. They may also have a protective effect on the accumulation of TG in the liver and the development of steatosis in animals. The results in man are more conflicting, especially in healthy subjects. Fortunately, positive results are observed in most studies conducted on subjects with raised lipid levels. In these subjects, inulin appears more effective than oligofructose; the effect on TG levels is larger than for cholesterol and, when present, these hypotriglyceridaemic and hypocholesterolaemic effects are comparable from one study to another. A decrease in liver de novo lipogenesis is probably the main mechanism responsible for the decrease in plasma TG levels, both in man and in animals, whereas the mechanism of the hypocholesterolaemic action remains uncertain. Further mechanistic studies are needed to resolve this. Further studies should also aim at determining whether inulin-type fructans may indeed protect against liver steatosis, and possibly against excess deposit of lipids in other tissues. Lastly, it is important to determine whether their effects are additive or not with other dietary (modifications of cholesterol amount or of the ratio of saturated to unsaturated fatty acids in the diet) or pharmacological intervention.

References

Insulin-type fructans and lipid metabolism

S167


Ellegård L, Andersson H & Bosaues L (1997) Inulin and oligofructose do not influence the absorption of cholesterol, or the excretion of cholesterol, Ca, Mg, Zn, Fe, or bile acids but increases energy excretion in ileostomy subjects. Eur J Clin Nutr 51, 1–5.


